title: Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan.
abstract: BACKGROUND
  Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated Plasmodium falciparum malaria in most areas of the world, where malaria is endemic, including Sudan. However, few published data are available on the use of ACT for treatment of P. vivax malaria.
  
  
  METHODS
  This study was conducted at a health centre in Kassala, eastern Sudan, from October to December 2011. Patients with uncomplicated P. vivax malaria received artemether-lumefantrine (AL) tablets (containing 20mg artemether and 120 mg lumefantrine) and were monitored for 28 days.
  
  
  RESULTS
  Out of the 43 cases enrolled in this study, 38 completed the 28-day follow-up. Their mean age was 25.1 years (SD: 1.5). On day 3 following AL treatment, all of the patients were afebrile and aparasitaemic. By day 28, all 38 patients exhibited adequate clinical and parasitological responses to AL treatment. The cure rate was 100% and 88.4% for the per protocol analysis andfor the intention to treat analysis, respectively. Mild adverse effects (nausea, vomiting, abdominal pain, dizziness and/or rash) that resolved spontaneously were observed in four (10.5%) of the patients.
  
  
  CONCLUSIONS
  AL combination therapy was fully effective for treatment of P. vivax malaria in the study in eastern Sudan.
  
  
  BACKGROUND
  Trial. Gov: NCT01625871.
authors.affiliation: Faculty of Medicine, Kassala University, Kassala, Sudan.
authors.forename: Tajeldin M
authors.initials: TM
authors.lastname: Abdallah
authors.forename: Abdel Aziem A
authors.initials: AA
authors.lastname: Ali
authors.forename: Mohammed
authors.initials: M
authors.lastname: Bakri
authors.forename: Gasim I
authors.initials: GI
authors.lastname: Gasim
authors.forename: Imad R
authors.initials: IR
authors.lastname: Musa
authors.forename: Ishag
authors.initials: I
authors.lastname: Adam
mesh_terms: D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D005449:Fluorenes / Q000008:administration & dosage*; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010966:Plasmodium vivax / Q000187:drug effects*; D013397:Sudan; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes